# US 5,344,919 A · Integrin from human epithelial cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,344,919 A
- Document ID: US5344919A
- Status: Granted
- Kind: A
- Application number: 08/014,090
- Filed: 1993-02-04
- Granted: 1994-09-06
- Earliest claimed: 1987-02-19
- Assignees: The Scripps Research Institute
- Inventors: Vito Quaranta; Shama Kajiji
- Web page: https://patentgrep.com/patent/US5344919A

## CPC

- C07K 16/303: {Liver or Pancreas}
- A61K 47/6859: {the tumour determinant being from liver or pancreas cancer cell}
- C07K 14/70546: {Integrin superfamily}
- C07K 16/2839: {against the integrin superfamily}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed. The antigens to which the antibodies of the invention are specific are characterized.

## Claims

### Claim 1

An isolated human heterodimeric protein complex of 400 kd by SDS PAGE or 500 kd by gel filtration which immunoreacts with Mab HB 9318 and that consists essentially of:
a) a first glycopeptide characterized by having apparent molecular weight in SDS-PAGE under reducing conditions of about 205 kd and under non-reducing conditions of about 190 kd, and glycosidase susceptibility to treatment with endo F and neuraminidase but not endo H, said first glycopeptide including the amino acid residue sequence N-R-C-K-K-A-P-V-K-S-C-T-E-C-V;
b) a second glycopeptide characterized by having apparent molecular weight in SDS-PAGE under reducing conditions of about 125 kd and under non-reducing conditions of about 150 kd, and glycosidase susceptibility to treatment with endo F, endo H and neuraminidase, said second glycopeptide including the amino acid residue sequence F-N-L-D-T-R-E-D-N-V-I-R-K-Y-G-D-P-G-S-L-F; and the deglycosylated and partially deglycosylated forms of said complex.